Baxter International Inc
A maker of essential hospital supplies, Baxter produces sterile IV solutions, infusion pumps, parenteral nutrition, surgical sealants, smart beds, and patient monitors sold in dozens of countries. Founded in 1931 by Dr. Donald Baxter and surgeon Ralph Falk, the company created the first factory-made sterile IV solutions in vacuum-sealed glass containers, replacing the contaminated hand-mixed fluids hospitals once brewed themselves. In 2025 it sold its Kidney Care business, Vantive.
Granted 569.9K
Granted 175.8K
Granted 301.5K
Granted 132.4K · Sold 64.5K
Granted 143.9K
Granted 115.0K
Granted 113.3K
Granted 128.5K
Granted 119.1K
Granted 26.0K
Granted 95.1K
Granted 59.5K
Granted 29.1K
Granted 61.4K
Granted 26.0K
Granted 26.0K
Granted 26.0K
Granted 13.1K
Granted 26.0K
Granted 26.0K
Granted 13.1K
Granted 716
Granted 23.5K
Granted 13.1K
Granted 14.6K
Granted 6.0K
Granted 29.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hider Andrew P.President and CEO, Director · 3 transactions | — | 572.2K | 569.9K | — | — |
| Almeida Jose EChairman, CEO, President · 6 transactions | — | 568.6Kas of Dec 2024 | 175.8K | — | — |
| Grade Joel T.EVP and CFO · 12 transactions | — | 271.7K | 301.5K | — | — |
| Mason Jeanne KEVP, Chief HR Officer · 11 transactions | +44% | 199.9K | 132.4K | — | 64.5K |
| Knight HeatherEVP, Chief Operating Officer · 9 transactions | +234% | 177.4Kas of Mar 2025 | 143.9K | — | — |
| Rosenbloom David S.EVP and General Counsel · 12 transactions | +148.4% | 138.2K | 115.0K | — | — |
| Sonig AlokEVP,Group President,Pharma · 8 transactions | +620.4% | 128.2K | 113.3K | — | — |
| Rasul ReazurEVP,Group Pres,Healthcare · 11 transactions | — | 125.6K | 128.5K | — | — |
| Toth Christopher A.EVP, Group Pres, Kidney Care · 4 transactions | — | 105.2Kas of Jan 2025 | 119.1K | — | — |
| Soriano Maria CeciliaGroup Pres., ITT & Pharma. · 5 transactions | — | 75.0K | 26.0K | — | — |
| Shafer David BrentDirector, Chair of the Board · 4 transactions | +925.3% | 72.8K | 95.1K | — | — |
| Borzi James WEVP,Chief Supply Chain Officer · 11 transactions | +258.3% | 71.9K | 59.5K | — | — |
| Wallace Steven P.President, Adv. Surgery · 1 transaction | — | 70.1K | — | — | — |
| Stevens BrianSVP, CAO & Controller · 6 transactions | +73.3% | 67.5Kas of Mar 2024 | 29.1K | — | — |
| Zielinski Anita ASVP, Interim CFO, CAO & Cntrlr · 4 transactions | — | 59.7K | 61.4K | — | — |
| Wendell Amy McBrideDirector · 3 transactions | +147.2% | 44.2K | 26.0K | — | — |
| Morrison PatriciaDirector · 3 transactions | +182.9% | 42.4K | 26.0K | — | — |
| Wilkes David S.Director · 3 transactions | +269.5% | 37.1K | 26.0K | — | — |
| Oesterle Stephen N.Director · 2 transactions | +68% | 35.8Kas of May 2025 | 13.1K | — | — |
| Schlichting Nancy MDirector · 3 transactions | +332.1% | 35.0K | 26.0K | — | — |
| Teaff JamesPresident, CCS · 1 transaction | — | 31.1K | — | — | — |
| Ampofo William A. IIDirector · 3 transactions | — | 30.4K | 26.0K | — | — |
| Smith Cathy RDirector · 2 transactions | +88.1% | 30.3Kas of May 2025 | 13.1K | — | — |
| Rasul ReazEVP, Group Pres, Healthcare · 2 transactions | +4.2% | 27.9Kas of Feb 2024 | 716 | — | — |
| Craig Jeffrey ADirector · 3 transactions | — | 23.7K | 23.5K | — | — |
| Rusckowski Stephen HDirector · 2 transactions | — | 16.5Kas of May 2025 | 13.1K | — | — |
| McDonnell Michael R.Director · 2 transactions | — | 14.6K | 14.6K | — | — |
| Wilver Peter MDirector · 1 transaction | +86.6% | 13.3Kas of May 2024 | 6.0K | — | — |
| Carlisle CynthiaExecutive Vice President, CHRO · 2 transactions | — | 0 | 29.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -64.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.